Cencora, Inc. $COR Stock Position Reduced by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lowered its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 60.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 234,389 shares of the company's stock after selling 352,525 shares during the period. Assenagon Asset Management S.A. owned approximately 0.12% of Cencora worth $72,096,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. State of Alaska Department of Revenue lifted its holdings in shares of Cencora by 56.1% in the third quarter. State of Alaska Department of Revenue now owns 36,891 shares of the company's stock valued at $11,077,000 after buying an additional 13,256 shares during the period. Turtle Creek Wealth Advisors LLC raised its position in Cencora by 42.6% in the third quarter. Turtle Creek Wealth Advisors LLC now owns 2,602 shares of the company's stock worth $781,000 after acquiring an additional 777 shares in the last quarter. Nvwm LLC lifted its holdings in Cencora by 44,950.0% in the 3rd quarter. Nvwm LLC now owns 2,703 shares of the company's stock valued at $812,000 after acquiring an additional 2,697 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Cencora by 81.5% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 447,763 shares of the company's stock valued at $139,917,000 after purchasing an additional 201,057 shares in the last quarter. Finally, Mather Group LLC. boosted its position in shares of Cencora by 119.0% during the 3rd quarter. Mather Group LLC. now owns 6,227 shares of the company's stock valued at $1,870,000 after purchasing an additional 3,383 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on COR shares. Bank of America lifted their price objective on shares of Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. Citigroup reissued a "buy" rating on shares of Cencora in a research note on Thursday, August 6th. Royal Bank Of Canada reissued a "sector perform" rating and set a $330.00 target price on shares of Cencora in a research note on Tuesday, September 8th. Leerink Partners raised their target price on shares of Cencora from $380.00 to $388.00 and gave the stock an "outperform" rating in a report on Wednesday, October 7th. Finally, Morgan Stanley raised their target price on shares of Cencora from $342.00 to $346.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $363.81.

Cencora Stock Down 0.3%

Cencora stock opened at $340.54 on Friday. The company has a market capitalization of $64.99 billion, a P/E ratio of 19.91, a P/E/G ratio of 1.75 and a beta of 0.58. The firm's fifty day simple moving average is $320.38 and its 200-day simple moving average is $303.34. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, beating analysts' consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. During the same quarter in the prior year, the firm posted $4.00 EPS. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. Sell-side analysts forecast that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, August 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora's dividend payout ratio is presently 17.83%.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the firm's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares of the company's stock, valued at $6,305,754.60. This trade represents a 36.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.38% of the stock is owned by company insiders.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.